In the United States, patients in psychiatric hospitals have the same right to refuse treatment as patients in other healthcare settings. However, if the treating team believes that the patient's safety or the safety of others is at risk, they may override it and provide treatment anyway in some situations. This decision must be based on carefully considering the patient's condition, the risks and benefits of treatment, and the potential consequences of not treating the patient.
Competence is a factor that may be considered in determining a patient's ability to refuse treatment, but it is not the only factor. Involuntary commitment does not automatically negate a patient's right to refuse treatment, such as in situations that require immediate intervention to prevent death or serious injury.

For a 10-year-old male diagnosed with ADHD, who has not responded to behavioral interventions and other nonpharmacological approaches, the first-line treatment option to consider is stimulant medication. Stimulant medications are widely recognized and approved by the Food and Drug Administration (FDA) for use in children and adolescents with ADHD. These medications are preferred as the initial pharmacological treatment due to their efficacy and rapid onset of action.
The main types of stimulant medications used in the treatment of ADHD include methylphenidate and amphetamines. These medications work by increasing the levels of neurotransmitters in the brain, specifically dopamine and norepinephrine, which play essential roles in attention and behavior regulation. The increase in these neurotransmitters helps to enhance attention span, focus, and impulse control, which are typically challenging areas for individuals with ADHD.
The primary effects of stimulant medication include improved attention span, decreased impulsivity, and reduced task-irrelevant activity. These changes can lead to significant improvements in academic performance, social interactions, and overall daily functioning. Additionally, stimulant medications generally help to decrease disruptive behaviors in various social settings, making it easier for the child to engage in age-appropriate activities and relationships.
It is important to monitor the child closely after initiating stimulant medication, as there can be potential side effects such as decreased appetite, difficulty sleeping, and increased anxiety or irritability. Regular follow-ups with the healthcare provider are crucial to assess the effectiveness of the medication, adjust dosages if necessary, and ensure that the benefits outweigh any possible adverse effects.
In cases where stimulant medications are not suitable or if they produce intolerable side effects, non-stimulant medications may be considered as alternative options. However, these are generally second-line treatments and might not be as effective as stimulant medications in managing the core symptoms of ADHD. Non-stimulant medications can include atomoxetine and some antidepressants, which also work on neurotransmitter systems but with different mechanisms and slower onset of effects compared to stimulants.
In conclusion, stimulant medication is the recommended first-line pharmacological treatment for a child with ADHD after nonpharmacological methods have not yielded sufficient improvement. These medications have a well-established efficacy profile for enhancing cognitive and behavioral symptoms associated with ADHD, thus improving the child's ability to function in academic and social settings.

In hypothyroidism, T4 is decreased and TSH is increased, producing slowed processes and depressive-like symptomatology. Patients with hypothyroidism may present with the following symptoms:
* Confusion
* Decreased libido
* Impotence
* Decreased appetite
* Memory loss
* Lethargy
* Constipation
* Headaches
* Slow or clumsy movements
* Syncope
* Weight gain
* Fluid retention
* Muscle aching and stiffness
* Slowed reflexes
* Somatic discomfort including aching and joint stiffness
* Slowed speech and thinking
* Sensory disturbances, including hearing
* Cerebellar ataxia
* Loss of amplitude in ECG
In hyperthyroidism, T4 is increased and TSH is decreased, which produces excitatory and labile/anxious-like symptomatology.
Other presentations of hyperthyroidism include the following:
* Motor restlessness
* Emotional lability
* Tremors
* Insomnia
* Impotence
* Weight loss
* Increased appetite
* Abdominal pain
* Excessive sweating
* Flushing
* Elevated upper eyelid leading to decreased blinking, staring, and fine tremors of the eyelid
* Tachycardia
* Dysrhythmias

SAM-e may cause hypomania, hyperactive muscle movements, and serotonin syndrome. It may decrease platelet aggregation but is not likely to increase blood coagulability. It is not known for inhibiting ovulation or altering glucose regulation.
Melatonin can inhibit ovulation in large doses. Vitamin E increases the anticoagulant effects. Fish oil can alter glucose regulation.

Confabulation is seen in some thought disorders, and it is defined as the fabrication of facts and details to fill gaps in memory.
Other common findings in thought disorders include blocking, echolalia, and neologisms.
* Blocking is the sudden stoppage of speech attributed to losing thought.
* Echolalia is the echoing of words or phrases just spoken by another.
* Neologisms are word inventions or unusual applications of current words.